Conference paper

WHAT DO LARGE SCALE STUDIES OF MEDICATION IN SCHIZOPHRENIA ADD TO OUR MANAGEMENT STRATEGIES?

Mark Agius ; South Essex Partnership University Foundation Trust, UK; Department of Psychiatry University of Cambridge, UK
Abigail Davis ; Clinical School University of Cambridge, UK
Michael Gilhooley ; Clinical School University of Cambridge, UK
Shelley Chapman ; Clinical School University of Cambridge, UK
Rashid Zaman ; South Essex Partnership University Foundation Trust, UK; Department of Psychiatry University of Cambridge, UK

Abstract

Introduction: A number of large naturalistic trials have reported in recent years comparing second generation antipsychotic drugs with their predecessors. The conclusions they draw have rightly sparked much debate, but are these studies truly comparable? If not, which of them are most methodologically robust and are these the studies most suitable as a foundation for clinical care guidelines with a strong evidence base. We aimed to conduct a review of the current literature to establish the appropriateness of several recent major clinical studies being used as the basis for clinical guidelines.
Method: A literature search using the PUBMED database was carried out. Five major studies comparing antipsychotic efficacy were selected as possible candidates and subjected to further analysis.
The studies were:

Keywords

anti-psychotics; effectiveness; efficacy; recovery; schizophrenia; first episode psychosis

Hrčak ID:

55849

URI

https://hrcak.srce.hr/55849

Publication date:

30.6.2010.

Visits: 2.045 *